MissionIR Small-Cap Investor Blog: May 2023

Tuesday, May 30, 2023

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Findings from DehydraTECH-CBD Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced additional findings from last year’s human clinical study HYPER-H21-4. The findings demonstrate significant reductions in several pro-inflammatory biomarkers known to be linked to cardiovascular disease (“CVD”) and a host of other conditions. “There is some pre-clinical evidence for the anti-inflammatory actions of CBD, but this is likely the most convincing evidence in humans that I have ever seen,” said Dr. Philip Ainslie, cardiovascular advisor to Lexaria and lead investigator of the HYPER-H21-4 study. “The bigger picture is that inflammation is the key basis of atherosclerosis, and several pro-inflammatory agents have been examined as potential mediators of the biochemical pathways of lesion formation. Other ‘common’ diseases or disorders associated with chronic inflammation include fatty liver disease; type 1 & 2 diabetes mellitus; inflammatory bowel disease; asthma; lung diseases chronic kidney disease; rheumatoid arthritis and obesity. Part of the reason why many of these diseases lead to cardiovascular disease is via chronic inflammation.”

To view the full press release, visit https://ibn.fm/aUJFb

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 30 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) to Deploy K5 ASR Service at the University of Nevada, Reno

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, today announced a new contract with the University of Nevada, Reno. According to the announcement, the university is subscribing to Knightscope’s K5 Autonomous Security Robot (“ASR”) service that utilizes robotics and artificial intelligence to provide 24/7/365 patrols in support of the University Police Department – Northern Command.

“In order to prevent crime from occurring in our educational institutions, it is crucial to invest in a wide array of approaches that systematically create safe, healthy and supportive schools for all students rather than just hardening access to them,” said William Santana Li, chairman and CEO of Knightscope. “Cutting-edge technologies like those offered by Knightscope are no longer a matter of luxury or convenience, but of best practices.”

To view the full press release, visit https://ibn.fm/L02I8

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

MissionIRNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) is a Leading Gainer in 5/22 Trading

D-Wave Quantum Inc. (NYSE: QBTS) is one of yesterday’s top gainers. The company’s shares closed at $1.02 for the day, a 110.70% increase from the previous closing price of $0.48. QBTS opened at $0.50 and reached a high of $1.06 and an intraday low of $0.50 throughout the day. The 46.6 million shares that traded represent an all-time trading volume record for the company.

D-Wave Quantum Inc. is a leader in quantum computing systems, software and services focused on delivering value to our customers via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow. Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computing solutions.

For more information, visit the company’s website at www.DWaveSys.com.

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave technology is being used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces Strategic Partnership with Amerit Fleet Solutions

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced Amerit Fleet Solutions as the provider for national service and warranty work, supporting Mullen’s commercial vehicle lineup, including the Mullen CAMPUS – EV Cargo Van, the Mullen ONE – Class 1 EV Van and the Mullen THREE – Class 3 EV Cab Chassis Truck programs. According to the announcement, Amerit will provide national fleet service and warranty repair work for these programs and, prior to launch, will be working closely with the Mullen commercial product team and vehicle technicians in Troy, Michigan, and Tunica, Mississippi, to train on Mullen’s commercial vehicles, establishing servicing protocols and requirements. “Amerit has over 1,800 highly trained vehicle service technicians across the U.S., and we have built our business and reputation on providing stellar servicing across many different fleet and commercial vehicle programs,” said Dan Williams, CEO of Amerit. “We look forward to providing Mullen and their fleet customers with the same high level of service and commitment.”

To view the full news release, visit https://ibn.fm/yZPxf

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in two company owned United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen Commercial Class 1 and 3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

MissionIRNewsBreaks – CISO Global Inc. (NASDAQ: CISO) CEO Recognized 2023 Phoenix Titan 100 Recipient

CISO Global Inc. (NASDAQ: CISO) CEO and founder David Jemmett has been named as a 2023 Phoenix Titan 100 recipient; this is the second year in a row that the CISO executive has been recognized with the award. CISO is an industry leader as a managed cybersecurity and compliance provider. According to the announcement, the Titan 100 program is designed to recognize Phoenix’s top 100 CEOs and C-level executives whose companies collectively employ more than 43,000 and generate an estimated $11 billion dollars in annual revenues; the executives come from an array of sectors, including technology, healthcare, construction/real estate, banking/finance, professional services, hospitality, human resources and nonprofit organizations, among others.

CISO has undergone an international expansion this past year, as well as a full rebrand; a cybersecurity industry leader and successful entrepreneur, Jemmett has facilitated that growth, which has also included 150% year-over-year growth in revenue from 2021. The executives who received the award are “changing the way that business is done in Phoenix,” the announcement noted. “I’m thrilled to be selected as a Titan 100 award recipient for the second consecutive year, and honored to be recognized alongside such an impressive group of Arizona business leaders,” said CISO Global CEO and founder David Jemmett in the press release. “CISO Global is on a mission to demystify and accelerate our clients’ journey to cyber resilience and we’re proud of the steps we continue to take toward that mission each day.”

To view the full press release, visit https://ibn.fm/WVgnt

About CISO Global Inc.

CISO Global is an industry leader as a managed cybersecurity and compliance provider. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations. For more information about the company, visit www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

MissionIRNewsBreaks – RYVYL Inc. (NASDAQ: RVYL) Releases Q1 2023 Financial Report, Corporate Update

RYVYL (NASDAQ: RVYL), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation to conduct payment transactions, is reporting on its first-quarter 2023 financial results. According to the report, the company’s revenues came in at a record $11.3 million, a 169% increase over the same period in 2022. Other highlights of the report included processing volume for the quarter reached an estimated $565 million, a 381% increase from the prior year same period and FX and international payments business, including Transact Europe totaled $344 million in business volume for the quarter. The company also reported that during the quarter, it had engaged Kingswood Capital Markets as a placement agent and advisor in connection with the strategic spin-off of coyni as well as the $40 million public offering and NASDAQ uplisting; the company also acquired Logicquest, a shell company, for the transfer of coyni’s assets in order to facilitate the spin-off transaction and inked a partnership agreement with global payment solutions leader, Intercash, designed to expand the Banking-as-a-Service platform in Europe. In addition, the company reported that six global financial institutions have signed up for the Banking-as-a-Service (BAAS) solution. “We are pleased to report a record first quarter 2023 of $11.3 million, outstanding growth from the prior year of 169%,” the company stated in the press release. “The first quarter was not without its challenges. Uncertainty surrounding the banking sector, coupled with expectations for increased regulation of digital payments and general macroeconomic concerns were common themes. Yet, we delivered against this backdrop with our best quarter ever.”

To view the full press release, visit https://ibn.fm/5Fo3k

About RYVYL

RYVYL was born from a passion for empowering a new way to conduct business-to-business, consumer-to-business and peer-to-peer payment transactions around the globe. By leveraging unique blockchain security and USD-pegged stablecoin technology with near real-time attestation, RYVYL is reinventing the future of financial transactions using its coyni(R) stablecoin platform as a transactional foundation. Since its founding as GreenBox POS in 2017, RYVYL has developed applications enabling an end-to-end suite of turnkey financial products with enhanced security and data privacy, world-class identity theft protection and rapid speed to settlement. As a result, the platform can log immense volumes of immutable transactional records at the speed of the internet for first-tier partners, merchants and consumers around the globe. For more information about the company, please visit www.GreenBoxPOS.com.

NOTE TO INVESTORS: The latest news and updates relating to RVYL are available in the company’s newsroom at https://ibn.fm/RVYL

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes $2 Million Public Offering Consisting of Common Shares and Accompanying Warrants

Lexaria recently completed its 2,106,000-unit public offering at $0.95 per share – representing proceeds totaling over $2 million gross in support of the company’s growth
Maxim Group LLC is acting as the sole placement agent in connection with Lexaria’s offering
Earlier the company was granted four new patents, bringing its total to 32 granted and many more pending worldwide for its patented DehydraTECH(TM) technology
Lexaria is currently seeking IND status from the FDA for use of DehydraTECH-processed CBD with hypertension and expects to begin dosing a new human clinical trial in October 2023

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the closing of its 2,106,000-unit public offering. Each unit consists of one share of common stock, and one warrant to purchase one share of common stock. The common shares and accompanying warrants can only be purchased together in this offering but will be issued by the company separately and will be separable upon issuance.

Each unit in Lexaria’s public offering is being sold at $0.95 and will be immediately exercisable at $0.95 per share and expire five years from the date of issuance. Maxim Group LLC is acting as the sole placement agent in connection with Lexaria’s offering. Before deducting the placement agent fees and other offering expenses, gross proceeds totaled approximately $2 million (https://ibn.fm/Bdr8d).

Lexaria’s patented DehydraTECH(TM) technology is designed to deliver lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (“APIs”) more effectively. The major benefits of DehydraTECH-enabled drugs or consumer products include:

Speeds up delivery – the subject feels the effects of the product in just minutes
Increases bioavailability – the technology is much more effective at delivering the drug or product into the bloodstream
Increases brain absorption – animal testing suggests significant improvement in the quantity of the drug delivered across the blood-brain barrier
Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect
Reduces drug administration costs – lower doses mean lower overall drug costs
Masks unwanted taste – the technology eliminates or reduces the need for sweeteners

Lexaria has demonstrated through animal studies a propensity for DehydraTECH to elevate the quantity of the drug delivered across the blood-brain barrier by as much as 1,700 percent, initiating additional new patent applications and opening possibilities for improved drug delivery. Since 2016, DehydraTECH has repeatedly demonstrated, through cannabinoids and nicotine, the ability to increase bio-absorption by up to five to ten times, reduce the onset time from one to two hours to just minutes, and mask unwanted tastes.

Lexaria is exploring additional orally administered bioactive molecules, including antivirals, cannabinoids, PDE5 inhibitors, oral nicotine and more.

The company currently has 32 granted patents, with several more pending worldwide – after recently being granted four new patents in Japan, Australia, Canada, and the United States. Lexaria believes that the U.S. patent could be of particular importance as it relates to the company’s pursuit of utilizing DehydraTECH-CBD in relation to its hypertension studies and its FDA Investigational New Drug application.

Phase 1b of Lexaria’s HYPER-H23-1 clinical trial, Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension, is expected to begin dosing as early as October 2023, after the filing of the IND with the FDA which is expected in this summer. The five previous (non-FDA regulated) human trials of DehydraTECH-CBD have shown potential to have pronounced clinical benefits relative to anti-hypertensive therapeutics.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all